Bio-pharmaceutical
Bio-pharmaceutical
The biomedical industry has experienced rapid economic growth and industrial transformation. Economically, it became the third-largest industry in the world after automobile and machinery manufacturing.
Synthetic biology, a new sub-category of biotechnology, can empower the development of the biomedicine industry. With the current development of synthetic biotechnology, global pharmaceutical companies' investment in this promising technology is vastly growing.
Abiochem is committed to using synthetic biology and revolutionary production methods to achieve a green, energy-saving, and efficient drug manufacturing environment. To date, synthetic biology technology has been successfully applied to the manufacturing of cardiovascular, diabetes, antiviral and antiepileptic drugs.
In addition, Abiochem has cooperated with a leading diabetes company to produce a generic version of Sitagliptin. This drug is expected to be the first domestic generic drug manufactured based on "non-hydrolase" biosynthetic methods, opening up a new chapter in biosynthetic pharmaceuticals.
Sitagliptin
Sitagliptin is the first dipeptidyl peptidase-IV (DPP-IV) inhibitor medicine, which is widely used in the treatment of type 2 diabetes. Using in vitro biosynthetic technique, Abiochem has developed the enzyme catalyst and mass production process for Sitagliptin with independent intellectual property rights. This biosynthetic enzyme can be re-utilized for tens of times under room temperature and pressure. It generates less industrial wastes with reduced energy consumption, and has significant advantage in the cost of production.
Dolutegravir
Dolutegravir is a highly potent orally administrated HIV integrase inhibitor, which is widely used in the treatment of AIDS. Based on its core platforms such as “Intelligent Design”, “Enzyme Engineering”, “Bioreaction Engineering” and “Material Synthesis”, Abiochem has developed the technique for the biosynthesis and mass production process of Dolutegravir with independent intellectual property rights. This technique has significant advantage with a simplified operation process, less industrial wastes, reduced energy consumption and carbon emission, which greatly lowered production cost making it very competitive within the industry.
